|Day Low/High||0.74 / 0.79|
|52 Wk Low/High||0.60 / 2.11|
Citigroup climbed back atop the stock-search list on TheStreet.com today, pushing Ford down a notch. AIG, State Street and Goldman Sachs were the day's only new entries.
Readers have their say on a recent bearish column about Cell Therapeutics.
Ford climbed to the top of the stock search list on TheStreet.com today, pushing Citigroup down a notch. Wells Fargo returned at No. 8 and People's United Financial appeared as the only new entry.
Frank Curzio's guests include David Peltier, Adam Feuerstein, and Larsen Kusick.
Citigroup reclaimed the top position in today's stock search list on TheStreet.com, pushing GE into second place. VMware, Cell Therapeutics and Hansen Natural are new to the list.
Investors are watching for key data from a handful of drug trials at this year's ASCO conference.
Cell Therapeutics is not the biotech turnaround story of the year, and here's why.
Fitzpatrick recently answered Stockpickr questions about Cell Therapeutics, shipping stocks and more.
Banks topped today's list of the most-searched-for stocks on TheStreet.com, with Citigroup, Bank of America and Wells Fargo at the No. 1, No. 2 and No. 3 spots, respectively. Newcomers to the list include Abbott, IBM and Sprint.
Dendreon remains No. 1 on TheStreet.com's list of most-searched-for stocks, with Citigroup and Ford holding the No. 2 and No. 3 slots, respectively. New to today's list are Cell Therapeutics, Sequenom and GE.
These speculative biotech stocks could be setting up to make significant moves in the near future.
Recently, TSC Ratings' Richard Widows answered questions about Textron, Cell Therapeutics and more.
Spectrum has a lot of work to do, but there are potentially positive signs that the company could succeed where others have failed.
Cell Therapeutics is selling off the remaining 50% stake in its cancer drug Zevalin for $18 million in a desperate bid to keep the company afloat.
Investors have a least three huge reasons to avoid this company.
Projecting potential market share for newly approved Relistor; monitoring exec moves at Introgen; and more.
As investors shy away from risk, this week's BIO CEO confab was a bleak affair.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.